Sign Up Now
Get instant access to over 1 million+ study documents
OR
Already registered? click here to login
By creating your account, you agree to our terms of service, privacy policy and student honor code.
Another study sponsored by these marketing firms was published in the August 2001 issue of the Neurology and claimed that it improved cognition, behavior and daily activity in 290 Alzheimer's patients, only 80 of whom had a severe stage. The effect of the drug on the majority of the patients tested was, therefore, uncertain and inconclusive. The former head of the Alzheimer's research for the National Institutes of Health, said that the modest effects of the drug on respondents fewer than several hundred to 1,000 people would be a problem. Exelon, a product of Novartis, and Reminy, a product of Johnson & Johnson's Janssen Pharmaceutica, were similar subjects of small, company-sponsored post-marketing studies. FDA rules say that companies cannot promote their drug products for off-label use or for purposes other than those approved by the FDA by providing doctors or researchers with scripts for their use at conferences and other professional gatherings. The companies were, however, allowed to sponsor conferences...
Pfizer Inc. And Eisai's public relations firm, Hill & Knowlton, recruited doctors to speak to news media about Alzheimer's and Aricept and also coached them on how to become effective "spokedoctors" for their product (Klotter).
Bibliography
1. Delagarza, Vincent W. Pharmacologic Treatment of Alzheimer's Disease. American Family Physician, 2003
2. Ebony. Important News for African-Americans in the Battle Against Alzheimer's Disease. Johnson Publishing, 2005
3. FDA Consumer. Second Alzheimer's Drug Ok'd. Food and Drug Administration: U.S. Government Printing Office, 1997
4. Klotter, Jule. Marketing Aricept for Alzheimer's Disease. Townsend Letter for Doctors and Patients: The Townsend Letter Group, 2002
5. Liebman, Bonnie. Tangled Memories. Nutrition Action Healthletter: Center for Science in the Public Interest, 2002
6.…
Bibliography
1. Delagarza, Vincent W. Pharmacologic Treatment of Alzheimer's Disease. American Family Physician, 2003
2. Ebony. Important News for African-Americans in the Battle Against Alzheimer's Disease. Johnson Publishing, 2005
3. FDA Consumer. Second Alzheimer's Drug Ok'd. Food and Drug Administration: U.S. Government Printing Office, 1997
4. Klotter, Jule. Marketing Aricept for Alzheimer's Disease. Townsend Letter for Doctors and Patients: The Townsend Letter Group, 2002
Therefore the cognitive performance wasn't improved significantly by the use of DHEA though in the 3 months period only a fleeting effect might have been observed (Wolkowitz et al., 2003, p.1073.) Vitamin E Vitamin is often prescribed by doctors for the treatment of Alzheimer disease. A large study which was funded by the federal government showed that the reduced ability to do daily activities is delayed slightly by the intake of
In light of the knowledge provided by these case studies, it is important to note certain flaws in the methodology of each cases study. The study in the case of midlife neuroticism, the researchers do not take into account pre- existing conditions such the brain structure and function associated with greater neuroticism. Failure to proper diagnosis might lead to early presentation of Alzheimer's disease in response to pathology. As for
Psychopharmacology Treatment for Alzheimers Disease The purpose of this paper is to evaluate the three treatment options for Mr. Akkad suffering from Alzheimer's disease. Mr. Akkad is a 76-year Iranian patient demonstrating some strange behaviors. The patient has started losing interest in the major religious activities, which is critical for a member of the family. Moreover, he has started abandoning things he uses to take very seriously before, and these things
What is worth noting here is the fact that behavior disturbances, ranging in severity from repeated questioning to physical violence, are common (National Institute of Mental Health, 1989). It is unclear whether Alzheimer's disease represents a single entity or several variants. Some experts believe that there are distinct subtypes of Alzheimer's disease, such as Lewy body disease (in which the signs of Parkinson's disease, visual hallucinations or alterations in alertness
S. will see average 44% increase in Alzheimer's disease by 2025. Type of information: This fact sheet describes the potential for growth in cases of Alzheimer's disease in the first quarter of this century. Specific Detail: 1. Southeastern and Western states will see the largest increases in Alzheimer's through 2025. 2. U.S. Census data notes that the number of Americans age 65 and over will double by 2025 3. Utah will see a 127%
diseases i.e. lung cancer, childhood leukemia, obesity and Alzheimer's disease. In each explanation, I have included a definition of the disease, risk factors, treatments, prognosis, and prevention. Later, I have provided short literature reviews of four articles. Lung Cancer Lungs are those organs in the body that help the human beings to breathe i.e. inhale and exhale oxygen. Their primary function is to provide oxygen to every cell in the body.